A recent study demonstrated that a liposome-based cancer vaccine containing ErbB-2 peptide and ovalbumin peptide OVA323-339 generated a rapid and high-titer anti-ErbB-2 antibody response in mice, increasing specific humoral immune responses by 7.3-fold in just 7 days [216]. This evidence concerns the gene ERBB2 and cancer.